Asensus Surgical (ASXC) M&A Announcement summary

Deal rationale and strategic fit

• KARL STORZ acquires Asensus Surgical to create a surgical robotics hub and drive Performance-Guided Surgery, enhancing its position in the robotic and digital surgical market.

• Asensus' expertise in robotic surgery and digital solutions complements KARL STORZ's endoscopy portfolio, supporting the development of the next-generation LUNA system.

• The acquisition aligns with both companies' philosophies and visions, leveraging Asensus' talent and technology for global healthcare impact.

Financial terms and conditions

• KARL STORZ acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash.

• Asensus Surgical has become a subsidiary of KARL STORZ, and its common stock has ceased trading on the NYSE American Exchange.

Synergies and expected cost savings

• The combination is expected to accelerate the development and delivery of innovative robotic and digital surgical solutions, benefiting patients and surgeons worldwide.

• Asensus' LUNA system, under development, is positioned to offer enhanced robotic precision and dexterity, complementing KARL STORZ's visualization capabilities.